MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a spray alter skin bacteria to help lymphoma lesions?
Disease control Not yet recruitingThis early-stage study tests a wound spray (APR-TD011) on skin lesions caused by cutaneous T cell lymphoma. Researchers want to see if the spray can reduce harmful bacteria (Staphylococcus aureus) on the skin and if it is well tolerated. The study will include 30 adults with earl…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktail takes on rare skin cancer
Disease control Not yet recruitingThis Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if …
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New antibody targets Hard-to-Treat skin cancer in first human trial
Disease control Not yet recruitingThis early-phase trial tests a new drug called DT-7012 for people with a rare type of skin lymphoma (CTCL) that has not responded to other treatments. The drug is an antibody designed to find and kill cancer cells in the skin and boost the immune system. About 30 adults with adva…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug aims to stop skin lymphoma from returning after transplant
Disease control Not yet recruitingThis phase 3 trial tests whether the drug brentuximab vedotin can prevent relapse in people with advanced cutaneous T-cell lymphoma (CTCL) who have recently had a stem cell transplant. About 84 adults with CD30-positive CTCL will receive either the drug or a placebo every three w…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 17:41 UTC